Novo Nordisk Faces Lawsuit Over Ozempic Vision Loss
A Nevada resident alleges the manufacturer failed to warn patients of the potential for permanent eye injury.
Updated on Oct. 30, 2026 in Diabetes
Maria David Patten has filed a lawsuit against Novo Nordisk in the U.S. District Court for the Eastern District of Pennsylvania. The complaint alleges that the use of Ozempic caused the plaintiff to suffer sudden and permanent vision loss.
Why it matters
The legal action highlights growing concerns regarding potential side effects of GLP-1 receptor agonists. The lawsuit contends that the company prioritized profits over providing adequate warnings about the risks of developing NAION.
A July 2024 Harvard study found that patients taking semaglutide were seven times more likely to develop NAION. The exact number of total lawsuits filed against the manufacturer regarding this condition is still under investigation.
The players
Maria David Patten
She is a Nevada resident who filed a lawsuit alleging that she suffered permanent vision loss after using Ozempic.
Novo Nordisk Inc.
It is a pharmaceutical company that manufactures popular GLP-1 receptor agonist medications including Ozempic and Wegovy.
The details
Patten claims that medical professionals confirmed her significant vision loss is permanent following her use of Ozempic. The filing is one of several similar lawsuits emerging against the manufacturer regarding Ozempic and Wegovy.
Timeline
July 2024: Harvard researchers published a study linking GLP-1 drugs to NAION.
October 19, 2026: Maria David Patten filed the lawsuit.
Health Landscape
This litigation follows the patterns identified in Harvard's July 2024 study on GLP-1 drugs and NAION. The lawsuit marks an escalation in public scrutiny regarding the safety profile of these widely used medications.
Patients currently prescribed Ozempic or similar GLP-1 medications should consult with their healthcare providers regarding any concerns about ocular health. This legal development serves as a reminder for users to remain vigilant for sudden changes in their physical well-being.
The takeaway
This case underscores the importance of ongoing monitoring for patients using chronic medication treatments. Consumers should discuss potential side effects with their doctors to better manage their personal health risks.
Further reading
For more information on the evolving safety profile of medications, visit the Diabetes section.
Source note: This article includes information reported by AboutLawsuits.
